Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Rituximab (MabThera) til behandling af aktiv reumatoid artritis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{51ddd286f63f4b089db406b38e1c9134,
title = "Rituximab (MabThera) til behandling af aktiv reumatoid artritis",
abstract = "Rituximab (RTX) is a murine/human monoclonal antibody to CD20, a protein expressed almost exclusively on human B-lymphocytes. RTX induces rapid and marked B-cell depletion with beneficial clinical effects in 1/3 to 1/2 of rheumatoid arthritis patients. Treatment is given as two iv. infusions with a two-week interval and in combination with methotrexate. Mild to moderate side-effects are frequent, particularly during the first infusion, but long-term side-effects are generally rare, although pulmonary events and reactivation of viral infections of the liver is of concern.",
author = "{El Fassi}, Daniel and Nielsen, {Claus Henrik} and Klaus Bendtzen",
year = "2006",
month = "11",
day = "20",
language = "Dansk",
volume = "168",
pages = "4079--81",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "47",

}

RIS

TY - JOUR

T1 - Rituximab (MabThera) til behandling af aktiv reumatoid artritis

AU - El Fassi, Daniel

AU - Nielsen, Claus Henrik

AU - Bendtzen, Klaus

PY - 2006/11/20

Y1 - 2006/11/20

N2 - Rituximab (RTX) is a murine/human monoclonal antibody to CD20, a protein expressed almost exclusively on human B-lymphocytes. RTX induces rapid and marked B-cell depletion with beneficial clinical effects in 1/3 to 1/2 of rheumatoid arthritis patients. Treatment is given as two iv. infusions with a two-week interval and in combination with methotrexate. Mild to moderate side-effects are frequent, particularly during the first infusion, but long-term side-effects are generally rare, although pulmonary events and reactivation of viral infections of the liver is of concern.

AB - Rituximab (RTX) is a murine/human monoclonal antibody to CD20, a protein expressed almost exclusively on human B-lymphocytes. RTX induces rapid and marked B-cell depletion with beneficial clinical effects in 1/3 to 1/2 of rheumatoid arthritis patients. Treatment is given as two iv. infusions with a two-week interval and in combination with methotrexate. Mild to moderate side-effects are frequent, particularly during the first infusion, but long-term side-effects are generally rare, although pulmonary events and reactivation of viral infections of the liver is of concern.

M3 - Tidsskriftartikel

VL - 168

SP - 4079

EP - 4081

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 47

ER -

ID: 31052506